Clinical Trial Update: CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a CDK4/6 inhibitor in combination with camrelizumab for PD-1 inhibitor-refractory recurrent/metastatic nasopharyngeal carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• CDK4/6 inhibitor
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN